Stockscreener 앱 받기
161.57
0.53%
0.85
시간 외 거래:
161.02
-0.55
-0.34%
전일 마감가:
$160.72
열려 있는:
$158
하루 거래량:
1.09M
Relative Volume:
0.81
시가총액:
$22.56B
수익:
$1.53B
순이익/손실:
$-214.69M
주가수익비율:
-91.80
EPS:
-1.76
순현금흐름:
$-43.68M
1주 성능:
-1.58%
1개월 성능:
+0.55%
6개월 성능:
+0.60%
1년 성능:
+45.95%
1일 변동 폭
$158.00
$163.23
1주일 범위
$158.00
$170.48
52주 변동 폭
$92.14
$183.00
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
NTRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
161.57 | 22.56B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
427.76 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
202.50 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
542.71 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.66 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
164.65 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
Natera Approves Equity Plan Amendment at Annual Meeting - TipRanks
DNA Testing Market Size, Share, and Forecast 2025-2033: Key - openPR.com
Natera: Growth Likely To Moderate, Despite Signatera Test Medicare Coverage (NASDAQ:NTRA) - Seeking Alpha
Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com
Where are the Opportunities in (NTRA) - news.stocktradersdaily.com
Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years - Benzinga
Insider Sell: Gail Marcus Sells 4,000 Shares of Natera Inc (NTRA) - GuruFocus
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase - Yahoo Finance
Transcript : Natera, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - MarketScreener
Prenatal Genetic Counselling Market 2025-2032: Top Trends & - openPR.com
Natera at Goldman Sachs Conference: Strategic Growth and Expansion - Investing.com Australia
Natera at Goldman Sachs Conference: Strategic Growth and Expansion By Investing.com - Investing.com India
Insider Sell: Steven Chapman Sells Shares of Natera Inc (NTRA) - GuruFocus
Colorectal Cancer Diagnostics Market Size To Boom with Top Key - openPR.com
Natera stock gains after Leerink Partners reiterates outperform rating By Investing.com - Investing.com South Africa
Natera's Signatera test to be covered under Medicare - MSN
Medicare expands coverage for Natera’s Signatera MRD test By Investing.com - Investing.com South Africa
Sector Update: Health Care - marketscreener.com
Natera Inc (NTRA) Trading 4.28% Higher on Jun 4 - GuruFocus
Natera (NTRA) Gains Medicare Coverage for Genome-Based Cancer Te - GuruFocus
Natera stock gains after Leerink Partners reiterates outperform rating - Investing.com
Natera's Signatera test to be covered under Medicare (NTRA:NASDAQ) - Seeking Alpha
Natera, Inc. Announces Medicare Coverage for Signatera Genome - marketscreener.com
Natera (NTRA) Secures Medicare Coverage for Signatera MRD Assay | NTRA Stock News - GuruFocus
Natera announces Medicare coverage for Signatera MRD assay - TipRanks
Medicare expands coverage for Natera’s Signatera MRD test - Investing.com Australia
Natera Announces Medicare Coverage for Signatera™ Genome | NTRA Stock News - GuruFocus
Natera Announces Medicare Coverage for Signatera ™ Genome - Business Wire
Natera Announces Medicare Coverage for Signatera™ Genome - New Castle News
Natera (NasdaqGS:NTRA) Showcases 94% Sensitivity In Pan-Cancer Signatera Genome Study - simplywall.st
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025 - GuruFocus
Natera Inc.: Is The Recent Growth in Signatera Volumes Here To Stay? - Smartkarma
Natera Inc (NTRA) Shares Up 3.07% on May 27 - GuruFocus
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
When the Price of (NTRA) Talks, People Listen - news.stocktradersdaily.com
Natera Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting | NTRA Stock News - GuruFocus
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting - Yahoo Finance
Natera raises 2025 revenue outlook to $1.94B-$2.02B with 26% growth target - MSN
Transcript : Natera, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 10 - marketscreener.com
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Stocks Showing Rising Market Leadership: Natera Earns 82 RS Rating - Investor's Business Daily
There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price - simplywall.st
Natera (NASDAQ:NTRA) Rating Lowered to “Sell” at StockNews.com - Defense World
Natera (NASDAQ:NTRA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Natera: The Clues In Q1 Earnings (NASDAQ:NTRA) - Seeking Alpha
NTRA: Piper Sandler Raises Price Target for Natera | NTRA Stock News - GuruFocus
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.61%
0.03%
자본화:
|
볼륨(24시간):